Clinical Studies & Publications

Our science makes cancer treatment effective, safe and harmless.

Arrow Down Icon

Pre-registration RIGVIR® clinical study summary


Clinical studies of RIGVIR® began in 1968 in Riga, Latvia

Read More

Adapted ECHO-7 virus RIGVIR® immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study


Doniņa, S., Strēle, I., Proboka, G., Auziņš, J., Alberts, P., Jonsson, B., Venskus, D., Muceniece, A.

An oncolytic, nonpathogenic ECHO-7 virus adapted for melanoma that has not been genetically modified (RIGVIR®) is approved and registered for virotherapy, an active and specific immunotherapy, in Latvia since 2004. The present retrospective study was carried out to determine the effectiveness of RIGVIR® in substage IB, IIA, IIB and IIC melanoma patients on time to progression and overall survival…

Full Article

Effect of the oncolytic ECHO-7 virus RIGVIR® on the viability of cell lines of human origin in vitro


Tilgase, A., Patetko, L., Blāķe, L., Ramata-Stunda, A., Borodušķis, M., and Alberts, P.

The role of oncolytic viruses in cancer treatment is increasingly studied. The first oncolytic virus (RIGVIR®, ECHO-7) was registered in Latvia over a decade ago. In a recent retrospective study RIGVIR® decreased mortality 4.39-6.57-fold in stage IB-IIC melanoma patients. The aims of the present study are to test the effect of RIGVIR® on cell line viability in vitro and to visualize the cellular presence of RIGVIR® by immunocytochemistry…

Full Article

Long term treatment with the oncolytic ECHO 7 virus RIGVIR® of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient‐three case reports


Alberts, P., Olmane, E., Brokāne L., Krastiņa, Z., Romanovska, M., Kupčs, K., Isajevs, S., Proboka, G., Erdmanis, R., Nazarovs, J., Venskus, D.

Oncolytic virotherapy is a recent addition to cancer treatment. Here, we describe positive treatment outcomes in three patients using RIGVIR® virotherapy…

Full Article

Melanoma Unknown Primary Brain Metastasis Treatment with ECHO-7 Oncolytic Virus RIGVIR®: A Case Report


Proboka, G., Tilgase, A., Isajevs, S., Rasa, A., Alberts, P.

Melanoma is considered an aggressive malignancy with a tendency of forming metastasis in the brain. Less than 10% of all melanoma cases present with unknown primary tumor location. This diagnose is yet to be fully understood, because there are only theoretical assumptions about the nature of the disease…

Full Article

Cancer Virotherapy Journal

Read More